fbpx

Clinical Trial for Limited-Stage Small Cell Lung Cancer (LS-SCLC)

This study is enrolling patients who are at least 18 years of age and have a new diagnosis of limited-stage small cell lung cancer (LS-SCLC). Limited stage lung cancer includes Stage I, II and III.

  • Everyone in the study will get platinum-doublet chemotherapy and radiation therapy at the same time.
  • Some patients will also get the investigational immunotherapy pembrolizumab.
  • Some patients will get both pembrolizumab and another investigational therapy called olaparib.

There are other criteria that you must meet to be part of the study.

Talk to your doctor or call 260-484-8830 to see if you may be eligible for this study designated KEYLYNK 103.

Image describing clinical trial for limited state small cell lung cancer

Eligibility Requirements

• Male or female at least 18 years of age on the day of signing informed consent
• Histologically or cytologically confirmed LS-SCLC (Stages I, II, III) that can be safely treated with definitive radiation doses and with no evidence of metastatic disease
• Has at least 1 lesion that meets the criteria for being measurable per RECIST 1.1
• Has not received prior treatment for LS-SCLC and is not expected to require tumor resection during the course of the study
• Able to submit a histologic or cytologic pre-treatment tumor tissue sample before or within 4 weeks after randomization
• ECOG score of 0 to 1 with a life expectancy of at least 6 months
• Adequate pulmonary and other organ function
There are additional eligibility criteria that will determine if a patient will qualify for study participation. The study team will talk with interested patients about study-related requirements/expectations and possible risks and benefits of study participation before they enroll.

Treatment Groups

Following screening, participants will be randomly assigned to 1 of 3 treatment groups.
• All study participants will receive platinum doublet chemotherapy and radiation therapy.
• Some participants will receive pembrolizumab and/or olaparib

Anticipated Study Duration

• Treatment will be approximately 15 months with additional long term follow up visits and/or phone calls.
• Participants can withdraw from this voluntary research study at any time.